Medtronic (MDT)

Health Care · $131B market cap · SEC CIK 0001613103

Next reports on Nov 24, 2026, with analysts expecting $1.34 in earnings per share.

52-week range $73.31 to $106.33. 4% below its 52-week high and 39% above its low.

The case for MDT

• Revenue growing 9.8% year over year.
• Pays a 3.5% dividend while you wait.
• Gross margin of 66% absorbs cost shocks.
• Moves less than the market (beta 0.58).
• Current assets cover the near-term bills 2.1 times over.

The case against

• Long-term debt of $26.2B against $1.9B of cash.
• Weakest against its peers: return on equity of 11% is lower than 59% of Health Care companies.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Medtronic's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Medtronic says it does

Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company. Medtronic was founded in 1949 and today serves healthcare systems, physicians, clinicians, and patients in more than 150 countries worldwide. We remain committed to a mission written by our founder in 1960 that directs us “to contribute to human welfare by the application of biomedical engineering in the research, design, manufacture, and sale of products to alleviate pain, restore health, and extend life.” Our Mission — to alleviate pain, restore health, and extend life — empowers us to engineer the extraordinary and deliver better outcomes for our world. We are a company of dedication, honesty, integrity, and service. Building on this strong foundation, we are embracing our role as a healthcare technology leader and evolving our business strategy in three key areas: • Accelerate innovation-driven growth: The combination of our…

Risk factors MDT lists in its 10-K

• We operate in a highly competitive industry and we may be unable to compete effectively
• Our success depends on our ability to differentiate our products and successfully execute and scale emerging technologies
• Reduction or interruption in supply or other manufacturing difficulties may adversely affect our manufacturing operations and related product sales
• Our research and development efforts rely upon investments and investment collaborations, and we cannot guarantee that any previous or future investments or investment collaborations will be successful
• We have debt obligations that create risk
• We are subject to extensive and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations
• Healthcare policy changes may have a material adverse effect on us
• We are subject to litigation, claims, investigations, and regulatory proceedings, which are inherently unpredictable and could materially adversely affect our business, results of operations, financial condition, and cash flows
• Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our business, results of operations, financial condition, and cash flows
• The outcome of Medtronic, Inc.'s U.S. tax litigation could have a material adverse impact on our financial condition
• Other Factors Impacting Our Operations
• Data Privacy and Security Laws and Regulations
• The failure to comply with anti-corruption laws could materially adversely affect our business and result in civil and/or criminal sanctions
• Laws and regulations governing international business operations could adversely impact our business
• Our insurance program may not be adequate to cover future losses
• Climate change or legal, regulatory or market measures to address climate change may materially adversely affect our financial condition and business operations
• We are subject to environmental laws and regulations and the risk of environmental liabilities, violations and litigation
• We are subject to risks related to our sustainability practices and initiatives
• We are subject to a variety of risks associated with global operations that could adversely affect our profitability and operating results
• Consolidation in the healthcare industry and the growing prevalence of ASCs could have an adverse effect on our revenues and results of operations
• Healthcare industry cost-containment measures could result in reduced sales of our medical devices and medical device components
• The continuing development of many of our products depends upon us maintaining strong relationships with healthcare professionals
• Market disruptions resulting in diminished liquidity, or strikes or other work stoppages by healthcare professionals or staff, could adversely affect our revenues, results of operation, or financial condition
• The ongoing separation of our Diabetes Business could be delayed, may not be completed as currently contemplated, and could materially adversely affect our business, results of operations, financial condition, and cash flows
• We are incorporated in Ireland, and our jurisdiction of incorporation may subject us to risks that could adversely affect our business and holders of our securities
• A transfer of our shares, other than ones effected by means of the transfer of book-entry interests in the Depository Trust Company, may be subject to Irish stamp duty
• As an Irish public limited company, we are required to obtain shareholder approval for certain capital structure decisions, which may limit our flexibility to manage our capital structure
• In certain limited circumstances, dividends we pay may be subject to Irish dividend withholding tax and dividends received by Irish residents and certain other shareholders may be subject to Irish income tax
• Our shares received by means of a gift or inheritance could be subject to Irish capital acquisitions tax

Filings

Other Health Care companies